BBOT · TickerCove

BBOTBridgeBio Oncology Therapeutics Inc.Healthcare · Biotechnologyas of 2026-09-16

Horizon

Issued 2026-09-16 at $4.76 · now $4.76 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, BBOT has typically landed between $4.03 and $5.58 — a range of −15.2% to +17.3% from the issuance price $4.76.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.

Actual close
Typical path (median)
Middle 50% of outcomes
90% range

631 overlapping 1 month windows · 2024-02-09 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($4.76) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

52-week range$4.76 · 0% of range

$4.76 low$13.73 high

Trailing 52 weeks to 2026-09-16 — factual context, not a signal.

Base rate up · monthiClimatology base rate that a US-listed stock rises over a month, with its 90% CI and ≈1,408 effective observations. Not a call on this stock — we have no evidence its odds differ.

53.9%

90% CI 51.7%–56.1%

Distribution · month iiThe price-anchored range: typical move (median), and the p90 downside/upside — 90% of similar periods stayed inside these. Ranges, not a prediction of direction.

+0.0%

typical move · IQR 3.2%

−15.2%worst (p90)+17.3%best (p90)

Insider convictioniOpen-market common-stock purchases by company insiders in the last 90 days (grants and option exercises excluded). Historical tendency, not advice — detail below.

conviction buys

0 open-market sales

Congress disclosuresiRecent disclosed congressional trades for this company. Purchase clusters (≥2 members buying within 90 days) historically preceded a modestly higher forward return (+32 bp/mo in 2022–2026, +45 bp/mo in 2015–2021) — a descriptive tendency, not a forecast input. Detail below.

0 buys · 0 sells · 0 members

cluster tilt persisted, ~halved after 2021

Where BBOT has typically landed a month from the 2026-09-16 close of $4.76 — the range is history, not a prediction.

now $4.76 (+0.0%)
typical $4.76 (+0.0%)
middle 50% $4.68–$4.84
90% range $4.03–$5.58

Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 631 windows spanning 2024-02-09 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.

Start	Return	Max drop	Max rise
3 worst
2026-08-12	−47.5%	−47.5%	+1.9%
2026-08-17	−47.3%	−47.3%	+6.2%
2026-08-14	−46.1%	−46.1%	+6.0%
3 best
2025-08-29	+29.5%	+0.0%	+35.2%
2025-08-22	+27.3%	+0.0%	+36.8%
2025-09-05	+26.6%	−1.7%	+26.6%

631 overlapping windows · 2024-02-09 – 2026-09-16 · not cherry-picked

Seasonality · by month i

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~3 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.

Jan

50%

−2.2%

n=2

Feb

50%

−5.6%

n=2

Mar

67%

−2.7%

n=3

Apr

−3.4%

n=3

May

33%

+1.5%

n=3

Jun

−5.5%

n=3

Jul

67%

+2.5%

n=3

Aug

33%

−2.6%

n=3

Sep

67%

−5.0%

n=3

Oct

50%

+1.4%

n=2

Nov

100%

+1.7%

n=2

Dec

100%

+1.1%

n=2

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Date	Person	Role	Action	Shares @ price	Value	Ownership Δ	vs S&P 1m	vs S&P 6m	Owned after	Filing

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

68 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

Date	Person	Role	Action	Shares	Owned after	Filing
2026-09-10	Cobo Marc	officer	Withheld for tax	203	14,141	Form 4
2026-09-10	Cobo Marc	officer	Award / grant	43,700	43,700	Form 4
2026-09-10	Cobo Marc	officer	Award / grant	9,038	14,344	Form 4
2026-07-01	Beltran Pedro	director	Withheld for tax	1,047	44,576	Form 4
2026-07-01	Ben Yong	director	Withheld for tax	1,047	44,576	Form 4
2026-07-01	Elmelech Idan	officer	Withheld for tax	343	14,495	Form 4
2026-07-01	Cobo Marc	officer	Withheld for tax	125	5,306	Form 4
2026-07-01	Chen Bihua	director	Other acquisition	130,865	6,083,221	Form 4
2026-07-01	Chen Bihua	director	Other acquisition	2,692,459	4,879,995	Form 4
2026-07-01	Chen Bihua	director	Other acquisition	1,704,862	5,010,332	Form 4
2026-07-01	Chen Bihua	director	Other acquisition	4,528,186	0	Form 4
2026-06-16	Kelleher Raymond J.	director	Award / grant	31,675	31,675	Form 4
2026-06-16	Lebowitz Peter F	director	Award / grant	7,289	7,289	Form 4
2026-06-16	MCCORMICK FRANK	director	Award / grant	31,675	31,675	Form 4
2026-06-16	Tipirneni Praveen P.	director	Award / grant	31,675	31,675	Form 4
2026-06-16	Bauer Jake	director	Award / grant	31,675	31,675	Form 4
2026-06-16	Kumar Neil	director	Award / grant	31,675	31,675	Form 4
2026-06-16	Chen Bihua	director	Award / grant	31,675	31,675	Form 4
2026-05-10	Elmelech Idan	officer	Award / grant	758,222	758,222	Form 4
2026-05-10	Beltran Pedro	director	Award / grant	1,103,837	1,103,837	Form 4
2026-04-01	Ben Yong	director	Withheld for tax	1,047	45,623	Form 4
2026-04-01	Beltran Pedro	director	Withheld for tax	1,047	45,623	Form 4
2026-04-01	Mehra Uneek	officer	Withheld for tax	524	22,806	Form 4
2026-03-24	Lebowitz Peter F	director	Award / grant	63,350	63,350	Form 4
2026-03-10	Mehra Uneek	officer	Award / grant	23,330	23,330	Form 4
2026-03-10	Mehra Uneek	officer	Award / grant	105,000	105,000	Form 4
2026-03-10	Beltran Pedro	director	Award / grant	46,670	46,670	Form 4
2026-03-10	Beltran Pedro	director	Award / grant	210,000	210,000	Form 4
2026-03-10	Ben Yong	director	Award / grant	46,670	46,670	Form 4
2026-03-10	Ben Yong	director	Award / grant	210,000	210,000	Form 4
2026-01-01	Wallace Eli M.	director	Award / grant	1,114,400	1,114,400	Form 4
2025-12-10	Wallace Eli M.	director	Disposition	1,114,400	500,000	Form 4
2025-12-10	Wallace Eli M.	director	Disposition	1,114,400	500,000	Form 4
2025-10-10	BridgeBio Pharma LLC	tenPercentOwner	Other acquisition	784,720	14,589,846	Form 4
2025-10-10	BridgeBio Pharma LLC	tenPercentOwner	Other acquisition	784,720	14,589,846	Form 4
2025-10-10	BridgeBio Pharma LLC	tenPercentOwner	Other acquisition	784,720	14,589,846	Form 4
2025-10-02	Wallace Eli M.	director	Award / grant	1,614,400	1,614,400	Form 4
2025-08-26	Beltran Pedro	director	Award / grant	357,177	357,177	Form 4
2025-08-26	Mehra Uneek	officer	Award / grant	633,570	633,570	Form 4
2025-08-26	Ben Yong	director	Award / grant	357,177	357,177	Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Resolves in i

28d remaining

2026-09-173% elapsed2026-10-15

Logged immutably 2026-09-17; scored automatically on 2026-10-15 — no edits, ever.

Earnings & context analysis

These panels are being prepared. They are generated by multiple language models, checked, and stored before display — never written live for a page view. Until a model panel has been generated and reviewed for a company, nothing is shown here, honestly, rather than a placeholder.

Calibration i

Every forecast is logged when made and scored when the month is up. The record is shown from the day it starts — young and honest.

How scoring works →

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

Reported insider & political trades

Congressional disclosures

Seasonality · by month i